Principal Financial Group’s SpringWorks Therapeutics SWTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,003,400
| Closed | -$47.1M | – | 2334 |
|
|
2025
Q2 | $47.1M | Sell |
1,003,400
-60,709
| -6% | -$2.7M | 0.02% | 471 |
|
|
2025
Q1 | $47M | Sell |
1,064,109
-39,749
| -4% | -$1.83M | 0.03% | 462 |
|
|
2024
Q4 | $39.9M | Buy |
1,103,858
+185,413
| +20% | +$6.48M | 0.02% | 535 |
|
|
2024
Q3 | $29.4M | Buy |
918,445
+464,903
| +103% | +$17.4M | 0.02% | 647 |
|
|
2024
Q2 | $17.1M | Buy |
453,542
+436,598
| +2,577% | +$18.4M | 0.01% | 962 |
|
|
2024
Q1 | $834K | Buy |
16,944
+824
| +5% | +$38.1K | ﹤0.01% | 1892 |
|
|
2023
Q4 | $588K | Buy |
16,120
+1,231
| +8% | +$32.1K | ﹤0.01% | 1926 |
|
|
2023
Q3 | $344K | Sell |
14,889
-458
| -3% | -$12.5K | ﹤0.01% | 2027 |
|
|
2023
Q2 | $402K | Buy |
15,347
+2,150
| +16% | +$56.5K | ﹤0.01% | 2002 |
|
|
2023
Q1 | $340K | Buy |
13,197
+1,008
| +8% | +$29.5K | ﹤0.01% | 2058 |
|
|
2022
Q4 | $317K | Buy |
12,189
+2,614
| +27% | +$64.4K | ﹤0.01% | 2087 |
|
|
2022
Q3 | $273K | Buy |
+9,575
| New | +$275K | ﹤0.01% | 2110 |
|
|
2022
Q2 | – | Sell |
-11,014
| Closed | -$621K | – | 2638 |
|
|
2022
Q1 | $621K | Buy |
11,014
+174
| +2% | +$9.96K | ﹤0.01% | 2071 |
|
|
2021
Q4 | $672K | Sell |
10,840
-5,233
| -33% | -$346K | ﹤0.01% | 2061 |
|
|
2021
Q3 | $1.02M | Buy |
16,073
+102
| +0.6% | +$7.86K | ﹤0.01% | 2002 |
|
|
2021
Q2 | $1.32M | Buy |
15,971
+1,289
| +9% | +$97.9K | ﹤0.01% | 1988 |
|
|
2021
Q1 | $1.08M | Sell |
14,682
-286
| -2% | -$22.4K | ﹤0.01% | 1979 |
|
|
2020
Q4 | $1.08M | Buy |
+14,968
| New | +$963K | ﹤0.01% | 1928 |
|
Other funds holding SWTX
Principal Financial Group's SWTX Position: Q3 2025 in Review
Principal Financial Group sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 1,003,400 shares — an estimated $47.1M sold.
Principal Financial Group first reported a position in SWTX in Q4 2020 and held it in 18 quarters. The position peaked at $47.1M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.
- Principal Financial Group reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
- Principal Financial Group sold 1,003,400 SpringWorks Therapeutics shares in Q3 2025, an estimated $47.1M.
- Principal Financial Group first reported a position in SpringWorks Therapeutics in Q4 2020 and held it in 18 quarters.
- Principal Financial Group's SpringWorks Therapeutics position peaked at $47.1M in Q2 2025.
- 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.
Based on Principal Financial Group's 13F filing for Q3 2025, filed 4 Nov 2025.